Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer

被引:77
作者
Gulmann, C
Sheehan, KM
Kay, EW
Liotta, LA
Petricoin, EF
机构
[1] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland
[2] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[3] NCI, FDA, Clin Prote Program, Pathol Lab, Bethesda, MD 20892 USA
[4] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA
关键词
proteomics; protein microarrays; biomarker discovery; bioinformatics; cancer;
D O I
10.1002/path.1958
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human proteome, due to the enormity of post-translational permutations that result in large numbers of isoforms, is much more complex than the genome and alterations in cancer can occur in ways that are not predictable by translational analysis alone. Proteomic analysis therefore represents a more direct way of investigating disease at the individual patient level. Furthermore, since most novel therapeutic targets are proteins, proteomic analysis potentially has a central role in patient care. At the same time, it is becoming clear that mapping entire networks rather than individual markers may be necessary for robust diagnostics as well as tailoring of therapy. Consequently, there is a need for high-throughput multiplexed proteomic techniques, with the capability of scanning multiple cases and analysing large numbers of endpoints. New types of protein arrays combined with advanced bioinformatics are currently being used to identify molecular signatures of individual tumours based on protein pathways and signalling cascades. It is envisaged that analysing the cellular 'circuitry' of ongoing molecular networks will become a powerful clinical tool in patient management. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:595 / 606
页数:12
相关论文
共 65 条
[41]  
Mori Y, 2003, CANCER RES, V63, P4577
[42]   Multiplexed sandwich assays in microarray format [J].
Nielsen, UB ;
Geierstanger, BH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 290 (1-2) :107-120
[43]  
Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO
[44]  
2-D
[45]   Meeting Review: The HUPO Proteomics Standards Initiative meeting: towards common standards for exchanging proteomics data - Hinxton, Cambridge, UK, 19-20 October 2002 [J].
Orchard, S ;
Kersey, P ;
Hermjakob, H ;
Apweiler, R .
COMPARATIVE AND FUNCTIONAL GENOMICS, 2003, 4 (01) :16-19
[46]   Proteomics to study genes and genomes [J].
Pandey, A ;
Mann, M .
NATURE, 2000, 405 (6788) :837-846
[47]   Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front [J].
Paweletz, CP ;
Charboneau, L ;
Bichsel, VE ;
Simone, NL ;
Chen, T ;
Gillespie, JW ;
Emmert-Buck, MR ;
Roth, MJ ;
Petricoin, EF ;
Liotta, LA .
ONCOGENE, 2001, 20 (16) :1981-1989
[48]   Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes [J].
Poon, TCW ;
Yip, TT ;
Chan, ATC ;
Yip, C ;
Yip, V ;
Mok, TSK ;
Lee, CCY ;
Leung, TWT ;
Ho, SKW ;
Johnson, PJ .
CLINICAL CHEMISTRY, 2003, 49 (05) :752-760
[49]   Computational analysis of microarray data [J].
Quackenbush, J .
NATURE REVIEWS GENETICS, 2001, 2 (06) :418-427
[50]   Analyzing array data using supervised methods [J].
Ringnér, M ;
Peterson, C ;
Khan, J .
PHARMACOGENOMICS, 2002, 3 (03) :403-415